id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3059855,3cefa065-7ccb-4d4b-9ca0-e8108ea2e77c,Q3,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2023,third_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2023-10-19T09:48:22-04:00
3059856,3cefa065-7ccb-4d4b-9ca0-e8108ea2e77c,Q3,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2023,third_quarter,CPT,"Issues related to intellectual property and patent reform, including: S.150, Affordable Prescriptions for Patients Act; S.79, Interagency Patent Coordination and Improvement Act; S.113, Prescription Pricing for the People Act; S.142, Preserve Access to Affordable Generics and Biosimilars Act; and S.148, Stop STALLING Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2023-10-19T09:48:22-04:00
3059857,3cefa065-7ccb-4d4b-9ca0-e8108ea2e77c,Q3,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2023,third_quarter,TRD,Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).,SENATE,60000,,0,0,2023-10-19T09:48:22-04:00